Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Tuesday 08 January, 2019

Verseon Corporation

Additional listing confirmation

RNS Number : 4915M
Verseon Corporation
08 January 2019
 

January 8, 2019

 

Verseon Corporation

("Verseon" or the "Company")

Additional listing confirmation

Fremont, Calif.- Further to the announcements made on 27 December 2018 and 3 January 2019, Verseon announces that the aggregated 50,639 new shares of common stock ("Common Shares") of par value US $0.001 issued will be admitted to trading on January 10, 2018 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,695,038 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,652,121. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.  

For further information, please contact:

Verseon Corporation

www.verseon.com

Sebastian Wykeham

+1 (510) 225 9000



Arden Partners (NOMAD and Joint Broker)


Ruari McGirr / Ciaran Walsh / Maria Gomez De Olea


+44 (0) 20 7614 5900



Cantor Fitzgerald Europe (Joint Broker) 


Phil Davies

+44 (0) 20 7894 7000



For financial and business media enquiries, please contact:

Buchanan Communications Ltd (PR Advisers)


Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000

 

For trade and pharma media enquiries, please contact:

Vane Percy & Roberts


Simon Vane Percy

+44 (0) 1737 821 890

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSUWAKRKWAARRR

a d v e r t i s e m e n t